Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8356951 | 0.79 | ALDH1A1 (0.40) | ALDH1A1ACACBL3MBTL1CCR1 | |
| SCHEMBL21186371 | 0.79 | ALDH1A1 (0.40) | ALDH1A1ACACBL3MBTL1CCR1 | |
| SCHEMBL5382170 | 0.79 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1 | |
| SCHEMBL2581847 | 0.79 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1 | |
| SCHEMBL18756351 | 0.69 | MMP1 (0.45) | ALDH1A1ACACB | |
| SCHEMBL19090742 | 0.67 | CA12 (0.43) | ACACB | |
| SCHEMBL30136924 | 0.67 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1 | |
| SCHEMBL7725268 | 0.66 | MEN1 (0.43) | ALDH1A1ACACB | |
| SCHEMBL2490744 | 0.66 | NPSR1 (0.46) | ALDH1A1 | |
| SCHEMBL5397200 | 0.66 | NPSR1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | ALDH1A1 4812/4885ACACB 4160/4885L3MBTL1 1065/4885 |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | ALDH1A1 4812/4885ACACB 4160/4885L3MBTL1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.